cytokine-mediated inflammation in ibd theresa t....
TRANSCRIPT
12/10/2009
1
CytokineCytokine--Mediated Inflammation in IBDMediated Inflammation in IBD
Theresa T. PizarroTheresa T. Pizarro
Department of Pathology, Case Western Reserve University
Andoh, et al., 2008
Mucosal Cytokine Network in IBD
12/10/2009
2
Adapted from Pizarro and Cominelli , J Immunol 2007
Cytokine group of ligands and receptors related by mechanisms of origin,receptor structure and common signal transduction pathways
Common Name IL-1 Family Name FunctionLigand-Binding
Chain
IL-1α IL-1F1 Agonist IL-1R type IIL-1β IL-1F2 Agonist IL-1R type IIL-1ra IL-1F3 Antagonist IL-1R type IIL-18 IL-1F4 Agonist IL-18R
IL-1F5 Agonist IL-1Rrp2IL-1F6 Agonist IL-1Rrp2IL-1F7 Unknown IL-18R IL-1F8 Agonist IL-1Rrp2IL-1F9 Agonist IL-1Rrp2
IL-1F10 Unknown UnknownIL-33 IL-1F11 Agonist ST2
Interleukin-1 (IL-1) Family
12/10/2009
3
Charles receives Crafoord Prize from the Royal Swedish National Academy ofSciences awarded by King Carl Gustaf of Sweden, May 11, 2009
• 2009 Albany Medical Center Prize in Medicine and Biomedical Research• 2010 Paul Ehrlich and Ludwig Darmstaedter Prize in the Field of Medicine
from the Federal Republic of Germany
IL-1 family members are synthesized as propeptides and are cleaved into theirmature forms by caspase-1, which is activated by the inflammasome
Franchi L, Nat Immunol 2009
12/10/2009
4
Cominelli et al., J Clin Invest 1990
12/10/2009
5
Casini-Raggi et al., J Immunol 1995
Carter et al., Gut 2001
Pizarro et al., J Immunol 1999
12/10/2009
6
Pizarro et al., J Imunol 1999
Corbaz et al., J Immunol 2002
12/10/2009
7
• Interleukin-33 (IL-33) is a novel cytokine,recently recognized as an Interleukin-1family member (Schmitz J, Immunity 2005)
• Expression of IL-33 has been shown inseveral types of cells, both haematopoietic(macrophages, DCs) and non-haematopoietic (fibroblasts, adipocytes,SMCs, ECs, IECs) (Schmitz J, Immunity2005)
• IL-33 is the ligand of the ST2 receptor,which is expressed by Th2 lymphocytesand mast cells, as well as fibroblasts andepithelial cells (Lohning M, PNAS 1998; XuD, J Exp Med 1998; Tago K, BiochemBiophys Res Commun 2001)
* Adapted from Schmitz J, Immunity 2005
§ Adapted from Arend WP, Immunol Rev 2008
Interleukin-33
*
§
IL-33 isoforms
Luthi et al., Immunity 2009
IL-33 was initially thought to be activated by the inflammasome throughcaspase-1 cleavage of a full-length form (30 kDa) in to an active form, similarlyto other IL-1 family members, recently it has been demonstrated that :
1) full-length IL-33 is the most bioactive form
2) Caspase-1 activation does not occur during physiological conditions
3) Pro-apoptotic caspases (-3 and -7) cleave IL-33 into less active 20-22 kDa forms
12/10/2009
8
Role of IL-33 as an “alarmin”
§ Carriere V, PNAS 2007; * Moussion C, PLoS ONE 2008
*
• Full-length IL-33 contains a nuclear localization sequence and a DNA-bindingdomain§; constitutively localized to the nucleus of endothelial and epithelialcells*
• No clear data regarding lL-33mechanism of secretion isavalaible; proposed release bysuffering/dying cells, acting as anovel alarmin*
• Thus, most bioactive IL-33 form(full length) may be releasedduring necrosis, and processedinto less potent, cleaved IL-33during apoptosis
ST2L
sST2
* Arend WP, Immunol Rev 2008
• IL-33: ligand for ST2 receptor; belongs to the Toll/IL-1R (TIR) superfamily
• ST2: expressed by Th2 lymphocytes and mast cells, as well as fibroblasts and epithelial cells
• 2 different splice variants of ST2 have been described:
- ST2L, localized to cell membrane
- sST2, soluble form functioning as decoy receptor
12/10/2009
9
•Kakkar et al., Nat Rev Drug Discov 2008•§ Ali et al., PNAS 2007
ST2L IL-1RAcP
IL-33
• ST2L requires the presence of IL-1RAcP in order to initiates the signaling cascade§
MyD88
• IL-33/ST2 signaling pathway involves MyD88, p38, JNK, NF-κB and AP-1*
NF-κB / AP-1
p38
• IL-33 induces Th2 cytokine production and potentiates both Th1 and Th2 responses
• exposure to IL-33 in the gut causes epithelial hyperplasia, neutrophil and eosinophil infiltration
• However, to date, no data regarding IL-33 and ST2 expression and role in IBD are available
* Adapted from Kakkar R, Nat Rev Drug Discov 2008
§ Adapted from Schmitz J, Immunity 2005
Potential role for IL-33 in the gut
PBS
IL-33
*
§
12/10/2009
10
Features of the SAMP1/YitFc (SAMP) mouse model of experimental Crohn’s disease
n Spontaneous ileitis without chemical, genetic or immunologic manipulation
n 100% penetrance by 12 wks; persistence of phenotype up to 80 wks of age
n Closely resembles human CD for disease location and histologic features
n Disease mediated by both Th1 and Th2 cytokines
n Responsive to standard CD therapies (i.e. steroids, anti-TNF)
n Earliest changes are characterized by epithelial cell alterations
Full-length IL-33 and sST2 are increased in UC inflamed mucosa
A
B
Pastorelli et al. submitted
12/10/2009
11
UC UC IEC
UC LPMC
CD
CONT
UC NEG
IL-33 is localized to IEC and LPMC in the inflamed mucosa of UC patients
Pastorelli et al. submitted
UC
UC IEC
UC NEG
CD
CONT CONT IEC
Immunolocalization of ST2 is altered in intestinal tissue from UC patients
Pastorelli et al. submitted
12/10/2009
12
Differential ST2 expression in epithelium of UC vs. inflammatory control patients
DIV
INF COLUC
Pastorelli et al. submitted
A
B
0
1
2
N=18 N=10 N=7
P<0.05
Re
lativ
e S
T2
mR
NA
ex
pre
ssio
n
0
8
16
N=18 N=10 N=7
P<0.05
P<0.05
Rel
ativ
e IL
-33
mR
NA
ex
pre
ss
ion
IL-33 expression is increased and ST2L is downregulatedin IEC from UC patients
Pastorelli et al. submitted
12/10/2009
13
0
500
1000
1500
2000
2500 P<0.001
N=59 N=72 N=19
SLD =5 pg/ml
P<0.01
IL-3
3 se
rum
lev
els
(pg
/ml)
0
200
400
600
800
1000
N=59 N=72 N=19
SLD =32 pg/m l
P<0.05
P<0.05
sST
2 se
rum
lev
els
(pg
/ml)
0
2
4
6
8
10
N=57 N=71 N=19
P<0.05
IL-3
3/sS
T2
Rat
io
B
A
IL-33 and sST2 serum levels are significantly increased in IBD patients and cleaved IL-33 is the main circulating form
Pastorelli et al. submitted
•Luca Pastorelli•Rekha Rani Garg•Benedetta Mattioli•Sharon Hoang•Xiao Ming Wang
ACKNOWLEDGEMENTSACKNOWLEDGEMENTS
•• Maurizio VecchiMaurizio VecchiUniversity of MilanoUniversity of Milano
•• Claudio FiocchiClaudio FiocchiCleveland Clinic FoundationCleveland Clinic Foundation
•• Fabio CominelliFabio CominelliCWRUCWRU